Tenaya Therapeutics is a privately-held biopharmaceutical company backed by The Column Group.  The Company was founded in 2016 by world-leading scientists from the Gladstone Institute’s Cardiovascular Division and the University of Texas Southwestern Medical Center.

Tenaya is dedicated to addressing heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration.

Tenaya has a lead gene therapy program focused on in vivo reprogramming of cardiac fibroblasts to cardiomyocytes to regenerate heart tissue, and additional programs focused on cardiomyopathies.